BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 30312417)

  • 1. Differences in the Epstein-Barr Virus gp350 IgA Antibody Response Are Associated With Increased Risk for Coinfection With a Second Strain of Epstein-Barr Virus.
    Smith NA; Baresel PC; Jackson CL; Ogolla S; Toko EN; Heit S; Piriou E; Sumba OP; Middeldorp JM; Colborn KL; Rochford R
    J Infect Dis; 2019 Feb; 219(6):955-963. PubMed ID: 30312417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High Levels of Antibody that Neutralize B-cell Infection of Epstein-Barr Virus and that Bind EBV gp350 Are Associated with a Lower Risk of Nasopharyngeal Carcinoma.
    Coghill AE; Bu W; Nguyen H; Hsu WL; Yu KJ; Lou PJ; Wang CP; Chen CJ; Hildesheim A; Cohen JI
    Clin Cancer Res; 2016 Jul; 22(14):3451-7. PubMed ID: 26920891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between Antibody Responses to Epstein-Barr Virus Glycoproteins, Neutralization of Infectivity, and the Risk of Nasopharyngeal Carcinoma.
    Zhu QY; Kong XW; Sun C; Xie SH; Hildesheim A; Cao SM; Zeng MS
    mSphere; 2020 Dec; 5(6):. PubMed ID: 33268566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant Epstein-Barr virus glycoprotein 350 as a serological antigen.
    Persson Berg L; Thomsson E; Hasi G; Bäckström M; Bergström T
    J Virol Methods; 2020 Oct; 284():113927. PubMed ID: 32650039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunization With Fc-Based Recombinant Epstein-Barr Virus gp350 Elicits Potent Neutralizing Humoral Immune Response in a BALB/c Mice Model.
    Zhao B; Zhang X; Krummenacher C; Song S; Gao L; Zhang H; Xu M; Feng L; Feng Q; Zeng M; Xu Y; Zeng Y
    Front Immunol; 2018; 9():932. PubMed ID: 29765376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-Epstein-Barr virus antibodies in Beijing during 2013-2017: What we have found in the different patients.
    Cui J; Yan W; Xu S; Wang Q; Zhang W; Liu W; Ni A
    PLoS One; 2018; 13(3):e0193171. PubMed ID: 29494658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High Epstein-Barr Virus Load and Genomic Diversity Are Associated with Generation of gp350-Specific Neutralizing Antibodies following Acute Infectious Mononucleosis.
    Weiss ER; Alter G; Ogembo JG; Henderson JL; Tabak B; Bakiş Y; Somasundaran M; Garber M; Selin L; Luzuriaga K
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27733645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Six anti-Epstein-Barr virus antibodies in healthy adults in a high risk area of nasopharyngeal carcinoma].
    Yi B; Gu YL; Zong YS; Cheng WM; Ji MF
    Ai Zheng; 2009 Aug; 28(8):822-6. PubMed ID: 19664327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Epstein-Barr virus (EBV) major envelope glycoprotein gp350/220-specific antibody reactivities in the sera of patients with different EBV-associated diseases.
    Xu J; Ahmad A; Blagdon M; D'Addario M; Jones JF; Dolcetti R; Vaccher E; Prasad U; Menezes J
    Int J Cancer; 1998 Oct; 79(5):481-6. PubMed ID: 9761116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced Transplacental Transfer of a Subset of Epstein-Barr Virus-Specific Antibodies to Neonates of Mothers Infected with Plasmodium falciparum Malaria during Pregnancy.
    Ogolla S; Daud II; Asito AS; Sumba OP; Ouma C; Vulule J; Middeldorp JM; Dent AE; Mehta S; Rochford R
    Clin Vaccine Immunol; 2015 Nov; 22(11):1197-205. PubMed ID: 26376931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of primary versus reactivated Epstein-Barr virus infection in patients with VCA IgG-, VCA IgM- and EBNA-1-antibodies and suspected infectious mononucleosis.
    Nystad TW; Myrmel H
    J Clin Virol; 2007 Apr; 38(4):292-7. PubMed ID: 17336144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the abbot Architect(™) epstein-barr virus viral capsid antigen IgM, viral capsid antigen IgG and nuclear antigen IgG assays in a pediatric and adult population.
    Grandjean Lapierre S; Vallières E; Rabaamad L; Labrecque M; Chartrand C; Renaud C
    J Clin Virol; 2016 Aug; 81():1-5. PubMed ID: 27258036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aberrant Epstein-Barr virus persistence in HIV carriers is characterized by anti-Epstein-Barr virus IgA and high cellular viral loads with restricted transcription.
    Stevens SJ; Smits PH; Verkuijlen SA; Rockx DA; van Gorp EC; Mulder JW; Middeldorp JM
    AIDS; 2007 Oct; 21(16):2141-9. PubMed ID: 18090040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maintenance of serum immunoglobulin G antibodies to Epstein-Barr virus (EBV) nuclear antigen 2 in healthy individuals from different age groups in a Japanese population with a high childhood incidence of asymptomatic primary EBV infection.
    Harada S; Kamata Y; Ishii Y; Eda H; Kitamura R; Obayashi M; Ito S; Ban F; Kuranari J; Nakajima H; Kuze T; Hayashi M; Okabe N; Senpuku H; Miyasaka N; Nakamura Y; Kanegane H; Yanagi K
    Clin Diagn Lab Immunol; 2004 Jan; 11(1):123-30. PubMed ID: 14715558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Schizophrenia is Associated With an Aberrant Immune Response to Epstein-Barr Virus.
    Dickerson F; Jones-Brando L; Ford G; Genovese G; Stallings C; Origoni A; O'Dushlaine C; Katsafanas E; Sweeney K; Khushalani S; Yolken R
    Schizophr Bull; 2019 Sep; 45(5):1112-1119. PubMed ID: 30462333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High prevalence of immunoglobulin A antibody against Epstein-Barr virus capsid antigen in adult patients with lupus with disease flare: case control studies.
    Chen CJ; Lin KH; Lin SC; Tsai WC; Yen JH; Chang SJ; Lu SN; Liu HW
    J Rheumatol; 2005 Jan; 32(1):44-7. PubMed ID: 15630723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased antibody levels to stage-specific Epstein-Barr virus antigens in systemic autoimmune diseases reveal a common pathology.
    Sternbæk L; Draborg AH; Østerlund MT; Iversen LV; Troelsen L; Theander E; Nielsen CT; Jacobsen S; Houen G
    Scand J Clin Lab Invest; 2019; 79(1-2):7-16. PubMed ID: 30727744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epstein-Barr Virus EA-IgA, VCA-IgA, and EBVNA-IgG Antibodies in a Population of Wuhan, China.
    Tang ZG; Li HH; Li YC; Lv MX; Xu X; Zeng JC; Kong WJ; Yang R
    Curr Med Sci; 2020 Feb; 40(1):168-171. PubMed ID: 32166679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum EBV EA-IgA and VCA-IgA antibodies can be used for risk group stratification and prognostic prediction in extranodal NK/T cell lymphoma: 24-year experience at a single institution.
    Huang Y; Rao H; Yan S; Wang F; Wu Q; Feng Y; Zhang Y
    Ann Hematol; 2017 Aug; 96(8):1331-1342. PubMed ID: 28550598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Relationship Between Environmental Factors and the Profile of Epstein-Barr Virus Antibodies in the Lytic and Latent Infection Periods in Healthy Populations from Endemic and Non-Endemic Nasopharyngeal Carcinoma Areas in China.
    He YQ; Xue WQ; Xu FH; Xu YF; Zhang JB; Yu HL; Feng QS; Chen LZ; Cao SM; Liu Q; Mu J; Zeng YX; Jia WH
    EBioMedicine; 2018 Apr; 30():184-191. PubMed ID: 29606628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.